SL
ADMA icon

Salomon & Ludwin’s ADMA Biologics ADMA Stock Holding History

Salomon & Ludwin’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2K Buy
3,068
+1,360
+80% +$21.5K ﹤0.01% 824
2025
Q4 		$30.8K Buy
1,708
+28
+2% +$472 ﹤0.01% 599
2025
Q3 		$24.6K Buy
+1,680
New +$28.8K ﹤0.01% 686

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Salomon & Ludwin's ADMA Position: Q1 2026 in Review

Salomon & Ludwin increased its ADMA Biologics (ADMA) stake by 80% in Q1 2026, buying an estimated $21.5K and bringing the position to 3,068 shares worth $28.2K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Salomon & Ludwin first reported a position in ADMA in Q3 2025 and has held it in 3 quarters since. The position peaked at $30.8K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Salomon & Ludwin held 3,068 shares of ADMA Biologics worth $28.2K as of Q1 2026.
  • Salomon & Ludwin bought 1,360 ADMA Biologics shares in Q1 2026, an estimated $21.5K.
  • ADMA Biologics made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #824 holding.
  • Salomon & Ludwin first reported a position in ADMA Biologics in Q3 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's ADMA Biologics position peaked at $30.8K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.